» Articles » PMID: 38638003

Mesenchymal Stromal Cells Increase the Natural Killer Resistance of Circulating Tumor Cells Via Intercellular Signaling of CGAS-STING-IFNβ-HLA

Overview
Journal Adv Sci (Weinh)
Date 2024 Apr 19
PMID 38638003
Authors
Affiliations
Soon will be listed here.
Abstract

Circulating tumor cells (CTCs) shed from primary tumors must overcome the cytotoxicity of immune cells, particularly natural killer (NK) cells, to cause metastasis. The tumor microenvironment (TME) protects tumor cells from the cytotoxicity of immune cells, which is partially executed by cancer-associated mesenchymal stromal cells (MSCs). However, the mechanisms by which MSCs influence the NK resistance of CTCs remain poorly understood. This study demonstrates that MSCs enhance the NK resistance of cancer cells in a gap junction-dependent manner, thereby promoting the survival and metastatic seeding of CTCs in immunocompromised mice. Tumor cells crosstalk with MSCs through an intercellular cGAS-cGAMP-STING signaling loop, leading to increased production of interferon-β (IFNβ) by MSCs. IFNβ reversely enhances the type I IFN (IFN-I) signaling in tumor cells and hence the expression of human leukocyte antigen class I (HLA-I) on the cell surface, protecting the tumor cells from NK cytotoxicity. Disruption of this loop reverses NK sensitivity in tumor cells and decreases tumor metastasis. Moreover, there are positive correlations between IFN-I signaling, HLA-I expression, and NK tolerance in human tumor samples. Thus, the NK-resistant signaling loop between tumor cells and MSCs may serve as a novel therapeutic target.

Citing Articles

Agonists and Inhibitors of the cGAS-STING Pathway.

Yu X, Cai L, Yao J, Li C, Wang X Molecules. 2024; 29(13).

PMID: 38999073 PMC: 11243509. DOI: 10.3390/molecules29133121.


Mesenchymal Stromal Cells Increase the Natural Killer Resistance of Circulating Tumor Cells via Intercellular Signaling of cGAS-STING-IFNβ-HLA.

Yi Y, Qin G, Yang H, Jia H, Zeng Q, Zheng D Adv Sci (Weinh). 2024; 11(21):e2400888.

PMID: 38638003 PMC: 11151078. DOI: 10.1002/advs.202400888.

References
1.
Morimoto Y, Kishida T, Kotani S, Takayama K, Mazda O . Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells. Biochem Biophys Res Commun. 2018; 507(1-4):330-336. DOI: 10.1016/j.bbrc.2018.11.035. View

2.
Bednarz-Knoll N, Alix-Panabieres C, Pantel K . Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev. 2012; 31(3-4):673-87. DOI: 10.1007/s10555-012-9370-z. View

3.
Kitamura T, Qian B, Pollard J . Immune cell promotion of metastasis. Nat Rev Immunol. 2015; 15(2):73-86. PMC: 4470277. DOI: 10.1038/nri3789. View

4.
Tirosh I, Izar B, Prakadan S, Wadsworth 2nd M, Treacy D, Trombetta J . Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016; 352(6282):189-96. PMC: 4944528. DOI: 10.1126/science.aad0501. View

5.
Yu R, Zhu B, Chen D . Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol Life Sci. 2022; 79(3):191. PMC: 8924142. DOI: 10.1007/s00018-022-04219-z. View